Triastek is selected as one of the recipient of the 2021 AAPS Best Abstract Award


At the recent 2021 AAPS annual meeting, Triastek’s conference paper "MED 3D Printed Tablets for Targeted Release in the Gastrointestinal Tract" was successfully selected as one of the recipients of the 2021 AAPS Best Abstract Award.

This paper by Triastek stood out among the 709 global submitted papers, ranking in the top 10%, with a selection rate of 2%, indicating the highly recognition of the innovation and leadership of Triastek in the field of 3D printing pharmaceuticals from industry professionals.

The American Association of Pharmaceutical Scientists is an international professional scientific organization. AAPS has built a good communication platform for pharmacists all over the world, with the mission of advancing the capacity of pharmaceutical scientists to develop products and therapies that improve global health.

This time, Triastek was selected as The AAPS "Best Abstract Award" conference paper, describing how to use 3D printing technology to design and develop targeted drug delivery in specific parts of the gastrointestinal tract (such as the stomach, small intestine, and colon). This kind of innovative drug delivery system helps to solve the dependence of traditional enteric-coated tablets on the pH of the gastrointestinal tract, and is conducive to achieving targeted drug release in the colon.

As a global leader in the field of 3D printing pharmaceuticals, Triastek has 131 international patent applications, accounting for more than 20% of the global 3D printing pharmaceutical field and it is the company with the most complete patent layout and the largest number of applications in this field. There are four 3D printed pharmaceutical products that have entered or completed the registration application in global, and Triastek contributed three of them. In July 2020, the United States Pharmacopoeia (USP) formally invited Triastek to participate in the formulation of industry standards for 3D printing pharmaceuticals.

On October 27th, Triastek officially announced its opening strategy of era 2.0: Commercialize 3D pharmaceutical printing technology by opening up technical resources and establishing relationships with global pharmaceutical companies.

Currently, Triastek’s 3D printing pharmaceutical equipment has been iterated more than ten times and has ten product pipelines. At the end of this year, Triastek will build a continuous production line for 3D printing pharmaceuticals with an annual capacity of 50 million tablets.

Copyright © 2024 (TRIASTEK)

Contact Us

Follow us on


COPYRIGHT © 2024 TRIASTEK. 苏ICP备17053162号